Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of JT001 (Deuremidevir) in Subjects with Renal Impairment
NCT05895812Phase 1Completed
- Sponsor
- Shanghai Vinnerna Biosciences Co., Ltd.
- Start
- May 2023
- Primary completion
- Aug 2023
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 1, open-label trial of deuremidevir in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by Shanghai Vinnerna Biosciences Co., Ltd. Primary endpoints: Maximum Plasma Concentration, Area Under the Curve from time zero to last measurable concentration and 8 more. Started May 2023; status: completed.
02
Drugs
deuremidevir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05895812.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05895812.